8-K: Kodak Q3 2025: Profit Surges, Pension Reversion Boosts Cash

Eastman Kodak Company reported strong third-quarter 2025 financial results, marked by significant increases in gross profit and Operational EBITDA, and an increased pension reversion amount.

Summary

• Consolidated revenues for Q3 2025 were $269 million, an increase of 3% compared to $261 million in Q3 2024.
• Gross profit increased by 51% to $68 million in Q3 2025 from $45 million in Q3 2024, with the gross profit percentage rising 8 points to 25%.
• GAAP net income for Q3 2025 was $13 million, a decrease of 28% from $18 million in Q3 2024.
• Operational EBITDA for Q3 2025 surged to $29 million, a $28 million increase from $1 million in Q3 2024.
• Advanced Materials & Chemicals (AM&C) revenues grew 15% to $82 million, and AM&C Operational EBITDA increased by $10 million to $16 million.
• Print revenues decreased by 3% to $177 million, but Print Operational EBITDA improved by $17 million, reaching $8 million from a negative $9 million.
• The quarter-end cash balance was $168 million, an increase of $13 million from June 30, 2025.
• The expected proceeds from the pension reversion transaction increased from $500 million to $600 million.
• Previously disclosed going concern conditions have been fully resolved.

Sentiment

Score: 8

Explanation: The filing indicates a very strong positive sentiment due to significant operational improvements, a substantial increase in Operational EBITDA, and the resolution of the 'going concern' issue. The increased pension reversion proceeds provide a major boost to the balance sheet and debt reduction efforts. While GAAP net income decreased, the underlying financial health and strategic progress are highly favorable.

Positives

• Gross profit increased significantly by 51% to $68 million in Q3 2025.
• Gross profit percentage improved by 8 percentage points to 25% in Q3 2025.
• Operational EBITDA saw a substantial increase of $28 million, reaching $29 million in Q3 2025.
• Advanced Materials & Chemicals (AM&C) segment revenues grew 15% to $82 million, driven by price increases and higher volumes in Industrial Film and Chemicals and Motion Picture.
• AM&C Operational EBITDA increased by $10 million to $16 million.
• Print Operational EBITDA improved by $17 million, turning from a negative $9 million in Q3 2024 to a positive $8 million in Q3 2025, primarily due to price increases, lower aluminum costs, and lower selling, general and administrative costs.
• The quarter-end cash balance increased by $13 million to $168 million from the prior quarter (June 30, 2025).
• The expected proceeds from the pension reversion transaction increased by $100 million, from $500 million to $600 million.
• Previously disclosed going concern conditions have been fully resolved, indicating improved financial stability.
• The AM&C group's cGMP pharmaceutical manufacturing facility is now certified to manufacture and sell regulated products.
• The AM&C unit's film business launched still films, aiming for greater control over the consumer film market and providing more stable pricing and reliable supply.
• The pension reversion will reduce term debt to $200 million, lowering interest expense and improving liquidity, resulting in the healthiest balance sheet in years.

Negatives

• GAAP net income decreased by $5 million or 28% to $13 million in Q3 2025 compared to Q3 2024.
• Print revenues decreased by $5 million or 3% to $177 million, primarily driven by lower volume related to Prepress Solutions.
• The cash balance at September 30, 2025, decreased by $33 million from December 31, 2024, primarily due to capital expenditures for growth initiatives and changes in working capital.
• Higher manufacturing costs partially offset improvements in Operational EBITDA for the Print segment.

Risks

• Ability to improve and sustain operating structure, cash flow, profitability, and other financial results.
• Ability to achieve strategic objectives, cash forecasts, financial projections, and projected growth.
• Ability to obtain additional or alternate financing if needed, manage worldwide cash, and provide/facilitate customer financing.
• Changes in foreign currency exchange rates, commodity prices, interest rates, and tariff rates.
• The timing and final amount of reversion proceeds actually received from the liquidation of the Kodak Retirement Income Plan (KRIP).
• Ability to fund continued investments, capital needs, collateral requirements, and to service debt and Series B Preferred Stock.
• Impact of the global economic environment, including inflationary pressures, geopolitical issues (war in Ukraine, conflicts involving Israel), medical epidemics, changes in trade policies, and ability to mitigate associated increased costs of raw materials, energy, labor, shipping, delays, and demand fluctuations.
• Ability to effectively compete with large, well-financed industry participants or competitors with lower cost structures.
• Performance by third parties of supply obligations and ability to address supply chain disruptions, especially for single or limited sources of supply.
• Ability to comply with covenants in various credit facilities.
• Ability to effectively anticipate technology and industry trends (including AI) and develop/market new products, solutions, and technologies.
• Ability to effect strategic transactions (investments, acquisitions, alliances, divestitures) or achieve their intended benefits.
• Ability to manage, defend, and resolve a variety of current and legacy claims without incurring material losses or disruptions.
• Ability to discontinue, sell, or spin-off certain non-core businesses or operations, or otherwise monetize assets.
• Potential impact of force majeure events, cyberattacks, data security incidents, or information technology (IT) outages.

Future Outlook

The company aims to expand its product offering over time from the newly certified cGMP pharmaceutical manufacturing facility. The AM&C film business intends to provide distributors, retailers, and consumers with more stable pricing and a broader, more reliable supply of still films. The surplus assets from the pension reversion will be used to pay down debt and strengthen the balance sheet, accelerating the plan to create a strong, growing Kodak. Management expresses confidence that continued execution of its plan will provide the necessary liquidity and remains committed to disciplined cash management, operational efficiencies, and margin improvement to deliver sustainable, long-term shareholder value.

Management Comments

• "Kodak delivered strong performance in the third quarter, delivering significant year-over-year increases in gross profit and Operational EBITDA while continuing to focus on driving operational excellence." Jim Continenza, Executive Chairman and CEO.
• "Our AM&C business continued to grow both revenue and profitability and that group's cGMP pharmaceutical manufacturing facility is now certified to manufacture and sell regulated products, with the goal of expanding our product offering over time." Jim Continenza.
• "By managing the process patiently and carefully we have obtained favorable annuity pricing and investment returns, which resulted in the expected reversion amount to increase from $500 million to $600 million." Jim Continenza.
• "The next step will be to use the surplus assets from the reversion to pay down debt and strengthen our balance sheet. The reversion frees us up to continue accelerating our plan to create a strong, growing Kodak for our employees and shareholders." Jim Continenza.
• "In Q3 we continued to improve our use of cash compared to Q2, increasing our cash balance to $168 million from $155 million at the end of the second quarter." David Bullwinkle, CFO.
• "We have taken decisive steps to strengthen and reduce debt levels on Kodak's balance sheet. The cash from the pension reversion will reduce our term debt to $200 million, lowering interest expense and improving liquidity, resulting in our healthiest balance sheet in years." David Bullwinkle.
• "We have confidence that the continued execution of our plan will provide the liquidity to fulfill our obligations. We remain committed to a disciplined approach to cash management, driving operational efficiencies and margin improvement to deliver sustainable, long-term value for our shareholders." David Bullwinkle.

Industry Context

The certification of Kodak's cGMP pharmaceutical manufacturing facility in the Advanced Materials & Chemicals segment positions the company to expand into high-value regulated product markets, aligning with broader industry trends towards specialized chemical production. The strategic launch of still films directly to distributors indicates a move to capture more value and control in the niche but resurgent consumer film market. The overall focus on operational excellence, debt reduction, and balance sheet strengthening reflects a common strategy for companies in mature or transforming industries seeking to enhance financial resilience and long-term competitiveness.

Corporate Governance

Stakeholder Impact

• Shareholders: Improved financial stability, increased cash, reduced debt, and strong operational performance are likely to enhance shareholder value and confidence.
• Employees: A new pension plan has been established for employees, identical to active employee benefit features of the prior plan.
• Creditors: The planned debt reduction from pension reversion proceeds will significantly strengthen the balance sheet, improving the company's ability to meet its obligations.
• Customers: The certification of the cGMP pharmaceutical manufacturing facility and the launch of still films aim to expand product offerings and provide more stable pricing and reliable supply.

Next Steps

• Use the surplus assets from the pension reversion to pay down debt and strengthen the balance sheet.
• Expand product offerings from the cGMP pharmaceutical manufacturing facility over time.
• Continue accelerating the plan to create a strong, growing Kodak for employees and shareholders.
• Maintain a disciplined approach to cash management, driving operational efficiencies and margin improvement.

Key Dates

Recommendation

The company has demonstrated a significant turnaround in operational profitability, with gross profit up 51% and Operational EBITDA surging by 2800%. The resolution of the 'going concern' issue, coupled with an increased pension reversion of $600 million earmarked for substantial debt reduction, fundamentally strengthens the balance sheet and removes a major financial overhang. The growth in the Advanced Materials & Chemicals segment, including new certifications and product launches, indicates strategic progress and future potential. While GAAP net income saw a slight dip, the underlying operational improvements and strategic financial de-risking make this a compelling investment opportunity for long-term growth.

Keywords

Kodak, KODK, financial results, Q3 2025, earnings, revenue, gross profit, EBITDA, pension reversion, debt reduction, Advanced Materials & Chemicals, Print, cGMP, pharmaceutical manufacturing, still film, corporate governance, going concern